Harbourvest Partners’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-12,276
| Closed | -$31.9K | – | 7 |
|
|
2025
Q4 | $31.9K | Hold |
12,276
| – | – | 0.02% | 6 |
|
|
2025
Q3 | $21.6K | Hold |
12,276
| – | – | 0.01% | 8 |
|
|
2025
Q2 | $17.1K | Hold |
12,276
| – | – | 0.02% | 14 |
|
|
2025
Q1 | $12.1K | Hold |
12,276
| – | – | 0.01% | 16 |
|
|
2024
Q4 | $16.1K | Hold |
12,276
| – | – | 0.01% | 22 |
|
|
2024
Q3 | $42.2K | Hold |
12,276
| – | – | 0.02% | 30 |
|
|
2024
Q2 | $40.5K | Hold |
12,276
| – | – | 0.02% | 33 |
|
|
2024
Q1 | $57.8K | Hold |
12,276
| – | – | 0.03% | 42 |
|
|
2023
Q4 | $89.6K | Hold |
12,276
| – | – | 0.03% | 47 |
|
|
2023
Q3 | $148K | Hold |
12,276
| – | – | 0.05% | 49 |
|
|
2023
Q2 | $130K | Hold |
12,276
| – | – | 0.04% | 51 |
|
|
2023
Q1 | $121K | Hold |
12,276
| – | – | 0.04% | 54 |
|
|
2022
Q4 | $181K | Hold |
12,276
| – | – | 0.06% | 52 |
|
|
2022
Q3 | $149K | Hold |
12,276
| – | – | 0.05% | 58 |
|
|
2022
Q2 | $172K | Hold |
12,276
| – | – | 0.06% | 54 |
|
|
2022
Q1 | $175K | Hold |
12,276
| – | – | 0.04% | 63 |
|
|
2021
Q4 | $259K | Hold |
12,276
| – | – | 0.03% | 57 |
|
|
2021
Q3 | $322K | Sell |
12,276
-2,471
| -17% | -$79.8K | 0.03% | 48 |
|
|
2021
Q2 | $460K | Buy |
14,747
+2,471
| +20% | +$80.9K | 0.04% | 39 |
|
|
2021
Q1 | $377K | Buy |
+12,276
| New | +$417K | 0.05% | 36 |
|
Harbourvest Partners's RPTX Position: Q1 2026 in Review
Harbourvest Partners sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 12,276 shares — an estimated $31.9K sold.
Harbourvest Partners first reported a position in RPTX in Q1 2021 and held it in 20 quarters. The position peaked at $460K in Q2 2021. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Harbourvest Partners reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Harbourvest Partners sold 12,276 Repare Therapeutics shares in Q1 2026, an estimated $31.9K.
- Harbourvest Partners first reported a position in Repare Therapeutics in Q1 2021 and held it in 20 quarters.
- Harbourvest Partners's Repare Therapeutics position peaked at $460K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Harbourvest Partners's 13F filing for Q1 2026, filed 15 May 2026.